Aerovate Therapeutics, Inc. (AVTE) News
Filter AVTE News Items
AVTE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AVTE News From Around the Web
Below are the latest news stories about AEROVATE THERAPEUTICS INC that investors may wish to consider to help them evaluate AVTE as an investment opportunity.
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionTopline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial |
Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3AVTE's Third Quarter Financials Show Continued Investment in Clinical Trials |
Aerovate Therapeutics Announces Third Quarter Financial Results and Business HighlightsWALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2023, and recent business highlights. Recent Highlights IMPAHCT Global Phase 2b/Phase 3 Clinical Trial on Track for Topline Data in the Second Quarter of 2024. IMPAHCT (Inhaled iMati |
12 Best Micro Cap Stocks To Invest InIn this piece, we will take a look at the 12 best micro cap stocks to invest in. To skip our introduction to micro cap investing, some benefits, and potential risks, you can skip ahead to 5 Best Micro Cap Stocks To Invest In. Depending on who you ask, it can be argued that the […] |
Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to IgnoreThe stock market is regularly affected by wider macro developments but that only paints part of the picture. While overall market conditions can push any stock down, when you zoom in, you’ll find that every stock writes its own story, with its own reasons for ups and downs, and savvy investors will make sure to do the background research, learning those idiosyncratic reasons, before buying in. Recognizing this, we’ve turned to some of the Wall Street analyst recommendations for pointers on two s |
TENX: Second Quarter ResultsBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 2Q:23 results on August 14, 2023 via its filing of Form 10-Q with the SEC. Despite the slow pace of advancement, we are impressed with the clinical data for both of Tenax’ PAH assets: levosimendan and imatinib. We see tremendous |
Aerovate Therapeutics Announces Second Quarter Financial Results and Business HighlightsWALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights. Recent Highlights Progress Continued for IMPAHCT Global Phase 2b/Phase 3 Clinical TrialExtended Cash Runway into 2026Presented Nonclinical Pharmacoki |
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Aerovate Therapeutics Appoints Habib Dable To Its Board of DirectorsWALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate’s Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biot |
TENX: Notice of Allowance Increases ConfidenceBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Additional Support for Oral Levosimendan Tenax Therapeutics, Inc. (NASDAQ:TENX) announced that the US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for its patent covering the use of oral levosimendan in pulmonary hypertension in patients with heart failure and preserved ejection fraction (PH-HFpEF). |